Market-Moving News for December 9th

XCUR: 176% | Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation achieved its primary endpoint.

SNTI: 44% | Senti Biosciences Says FDA Grants Regenerative Medicine Advanced Therapy Designation To SENTI-202 For Treatment Of R/R Hematologic Malignancies, Including AML

VOR: 75% | JP Morgan Initiates Coverage On Vor Biopharma with Overweight Rating, Announces Price Target of $43